Company profile: Mezzion Pharma
1.1 - Company Overview
Company description
- Provider of pharmaceuticals developing and discovering medicines, including JURVIGO (udenafil), a medication to improve physiology and exercise capacity in patients aged 12+ with Fontan circulation. Supports clinical programs: FUEL-2 phase 3 trial evaluating udenafil in adolescents 12–18, FALD study on long-term liver effects, and FUEL OLE study on long-term safety.
Products and services
- FUEL Open Label Extension (OLE) Study: An open-label extension assessing the long-term safety of udenafil after administration in patients with Fontan circulation
- FUEL-2 Clinical Trial: A phase-3 clinical trial evaluating the effectiveness of udenafil in adolescents aged 12–18 with Fontan circulation
- JURVIGO (udenafil): A udenafil-based medication aimed at improving the physiology and exercise capacity of patients aged 12 years and older with Fontan circulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mezzion Pharma
Hyloris Pharmaceuticals
HQ: Belgium
Website
- Description: Provider of specialty pharmaceutical therapies, including Sotalol IV for atrial fibrillation (developed with AltaThera), Maxigesic IV, a non-opioid analgesic for post-operative pain combining paracetamol and ibuprofen sodium dihydrate (developed with AFT Pharmaceuticals), and Podofilox Gel 0.5% for anogenital warts, equivalent to Condylox.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hyloris Pharmaceuticals company profile →
enVVeno Medical
HQ: United States
Website
- Description: Provider of bioprosthetic devices for cardiovascular surgeries, including VenoValve, a surgically implanted one-way valve to restore proper blood flow in the femoral vein for patients with deep venous Chronic Venous Insufficiency (CVI), and enVVe, a non-surgical, transcatheter-based replacement venous valve for minimally invasive treatment of CVI in the deep veins of the leg.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full enVVeno Medical company profile →
Impulse Dynamics
HQ: United States
Website
- Description: Provider of innovative medical device solutions for the treatment of chronic heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Impulse Dynamics company profile →
Techdevice
HQ: France
Website
- Description: Provider of industrial equipment products for the transportation, medical, energy and data communications industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Techdevice company profile →
PerSys Medical
HQ: United States
Website
- Description: Provider of specialized medical and emergency products for military, law enforcement, homeland security, and EMS agencies, including the SWAT-T tourniquet, Russell Chest Seal, Celox Rapid B-CON hemostatic device, Warrior Blood & Fluid Warmer Set, Bleed Control Kit, and TruBODIES reanimated tissue training system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PerSys Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mezzion Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mezzion Pharma
2.2 - Growth funds investing in similar companies to Mezzion Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mezzion Pharma
4.2 - Public trading comparable groups for Mezzion Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →